This company has been acquired
Cidara Therapeutics Management
Management Kriterienprüfungen 3/4
Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.
Wichtige Informationen
Jeff Stein
Geschäftsführender
US$6.0m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 10.35% |
| Amtszeit als Geschäftsführer | 12yrs |
| Eigentum des Geschäftsführers | 0.2% |
| Durchschnittliche Amtszeit des Managements | 3.4yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 5yrs |
Jüngste Management Updates
Recent updates
Expanded Phase III Trial And BARDA Support Will Shape Long Term Outlook
Catalysts About Cidara Therapeutics Cidara Therapeutics develops drug Fc conjugates aimed at preventing and treating serious infectious diseases such as influenza. What are the underlying business or industry changes driving this perspective?Cidara: Merck's Acquisition Based On CD388 Flu Prevention Potential
Summary Cidara Therapeutics delivered a 1,165%+ return, driven by positive CD388 data and Merck's $221.50/share acquisition offer. CD388 achieved statistically significant prevention efficacy up to 76% in phase 2b, leading to FDA alignment for the single pivotal phase 3 ANCHOR trial. Phase 3 ANCHOR trial reached 6,000-patient enrollment; interim analysis is expected Q1 2026, with BLA submission contingent on success for this and subsequent Southern Hemisphere study start. I maintain a "Hold" rating as the Merck acquisition awaits HSR clearance, with regulatory and competitive risks remaining. Plus, no further upside as the acquisition is already announced. Read the full article on Seeking AlphaBullish On Cidara Therapeutics As It Doubles Down On CD388 For Universal Flu Prevention
Summary Cidara Therapeutics is leveraging its Cloudbreak platform to develop CD388 for universal influenza prophylaxis. Fortunately, they recently enrolled 5,000 subjects in its Phase 2b trial to assess CD388’s safety and efficacy. CD388 inhibits viral replication and activates the immune response, and its mechanism of action actually received the FDA’s Fast Track designation. Interestingly, CDTX reduced its workforce by 30% to concentrate on CD388. This could very well pay off if they're successful with their 2025 trials. Overall, CDTX stock trades at a reasonable valuation, so I feel it’s fair to give it a speculative “Buy” rating as a bet on CD388 in 2025. Read the full article on Seeking AlphaCidara Therapeutics: The underestimated potential of CD388
CD388 is a universal long-lasting influenza drug against all seasonal and pandemic influenza viruses in a phase 2b clinical trial. CD388 is not a vaccine but would provide 6 months of protection.Cidara spikes on $11M milestone payment from partner Mundipharma
The shares of clinical-stage biotech Cidara Therapeutics (NASDAQ:CDTX) gained over 8% pre-market Tuesday after the company announced that British drugmaker Mundipharma paid $11.1M as a milestone payment under a 2019 licensing deal. The payment follows the acceptance of the marketing authorization application (MAA) for rezafungin by the European Medicines Agency (EMA) as a treatment for fungal diseases candidemia and invasive candidiasis. While CDTX has rights for rezafungin in Japan, the company has sold the U.S. commercial rights for the drug to Melinta Therapeutics and rights for all other territories to Mundipharma. Chief Executive Jeffrey Stein said that his company remains on track to receive up to ~$108M in milestone payments as additional non-dilutive capital from partners subject to the accomplishment of events scheduled for the next two years. Read more about the CDTX’s licensing deal for rezafungin with Melinta in the U.S.Cidara begins dosing of antiviral CD388 in trial for preventing influenza
Cidara Therapeutics (NASDAQ:CDTX) said it began dosing in a phase 2a trial of CD388 to evaluate the pre-exposure prophylactic activity of the antiviral against influenza virus. CD388 is aimed to deliver universal prevention of seasonal and pandemic influenza, the company said in A a Sept. 13 press release. Cidara said the study is being conducted under an exclusive worldwide license and collaboration with Johnson & Johnson (NYSE:JNJ), to develop and commercialize Cidara's Cloudbreak drug-Fc conjugates (DFCs) to prevent seasonal and pandemic influenza. Multiple dose levels of CD388 will be evaluated in people who will receive a single administration of CD388 or placebo prior to influenza viral challenge. The trial is expected to enroll up to 168 healthy adults. "Because of its mode of action, CD388 has the potential to enable universal influenza coverage against all viral strains for all people, including those with compromised immune systems. We look forward to announcing the findings next year, and continuing our collaboration with Janssen who will be spearheading late-stage development," said Cidara President and CEO Jeffrey Stein.Cidara Therapeutics GAAP EPS of -$0.19 beats by $0.09, revenue of $6.22M beats by $0.01M
Cidara Therapeutics press release (NASDAQ:CDTX): Q2 GAAP EPS of -$0.19 beats by $0.09. Revenue of $6.22M (-81.1% Y/Y) beats by $0.01M.Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$185m |
| Jun 30 2025 | n/a | n/a | -US$117m |
| Mar 31 2025 | n/a | n/a | -US$186m |
| Dec 31 2024 | US$6m | US$618k | -US$170m |
| Sep 30 2024 | n/a | n/a | -US$126m |
| Jun 30 2024 | n/a | n/a | -US$114m |
| Mar 31 2024 | n/a | n/a | -US$26m |
| Dec 31 2023 | US$2m | US$594k | -US$25m |
| Sep 30 2023 | n/a | n/a | -US$34m |
| Jun 30 2023 | n/a | n/a | -US$18m |
| Mar 31 2023 | n/a | n/a | -US$22m |
| Dec 31 2022 | US$1m | US$566k | -US$22m |
| Sep 30 2022 | n/a | n/a | -US$33m |
| Jun 30 2022 | n/a | n/a | -US$63m |
| Mar 31 2022 | n/a | n/a | -US$44m |
| Dec 31 2021 | US$2m | US$566k | -US$42m |
| Sep 30 2021 | n/a | n/a | -US$47m |
| Jun 30 2021 | n/a | n/a | -US$47m |
| Mar 31 2021 | n/a | n/a | -US$74m |
| Dec 31 2020 | US$1m | US$542k | -US$75m |
| Sep 30 2020 | n/a | n/a | -US$67m |
| Jun 30 2020 | n/a | n/a | -US$47m |
| Mar 31 2020 | n/a | n/a | -US$42m |
| Dec 31 2019 | US$1m | US$526k | -US$41m |
Vergütung im Vergleich zum Markt: JeffDie Gesamtvergütung ($USD5.97M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD8.35M).
Entschädigung vs. Einkommen: JeffDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.
Geschäftsführer
Jeff Stein (70 yo)
Dr. Jeffrey L. Stein, Ph D., also known as Jeff, has been the Chief Executive Officer, President and Executive Director of Cidara Therapeutics, Inc. since January 2014. Dr. Stein served as Principal Financ...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| President | 12yrs | US$5.97m | 0.23% $ 16.2m | |
| Chief Scientific Officer | 4.5yrs | US$2.04m | 0.035% $ 2.5m | |
| Chief Financial Officer | less than a year | keine Daten | keine Daten | |
| COO & Corporate Secretary | 4.4yrs | US$929.86k | 0.079% $ 5.5m | |
| Senior Vice President of People & Culture | 5yrs | keine Daten | keine Daten | |
| Chief Medical Officer | 2.4yrs | keine Daten | 0.066% $ 4.6m | |
| Chief Business Officer | 1.4yrs | keine Daten | keine Daten | |
| Senior Vice President of Clinical Development | less than a year | keine Daten | keine Daten |
Erfahrenes Management: CDTXDas Führungsteam des Unternehmens gilt als erfahren (3.4 Jahre durchschnittliche Betriebszugehörigkeit).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| President | 12yrs | US$5.97m | 0.23% $ 16.2m | |
| Independent Chairman of the Board | 11.8yrs | US$451.51k | 0.00048% $ 33.5k | |
| Independent Director | 11.8yrs | US$423.51k | 0% $ 0 | |
| Independent Director | 5yrs | US$331.56k | 0.000050% $ 3.5k | |
| Independent Director | 5yrs | US$332.29k | 0% $ 0 | |
| Independent Director | 7.8yrs | US$391.10k | 0.011% $ 734.9k | |
| Independent Director | 1.8yrs | US$85.52k | 0% $ 0 | |
| Independent Director | 1.8yrs | US$88.26k | 0% $ 0 | |
| Director | 1yr | keine Daten | keine Daten |
Erfahrener Vorstand: CDTXDie Vorstandsmitglieder gelten als erfahren (5 Jahre durchschnittliche Amtszeit).
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/01/06 06:50 |
| Aktienkurs zum Tagesende | 2026/01/06 00:00 |
| Gewinne | 2025/09/30 |
| Jährliche Einnahmen | 2024/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Cidara Therapeutics, Inc. wird von 8 Analysten beobachtet. 6 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Timothy Chiang | BTIG |
| Eun Kyung Yang | Jefferies LLC |
| Kevin DeGeeter | Ladenburg Thalmann & Company |